Topical composition for relieving dry skin symptoms associated with atopic dermatitis and eczema
A topical moisturizer composition with a blend of ingredients synergistically addresses atopic dermatitis symptoms, enhancing skin hydration and barrier repair, thus improving treatment efficacy and compliance.
Patent Information
- Application Number
- PCT/IN2026/050048
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-01-12
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for atopic dermatitis, such as topical corticosteroids and calcineurin inhibitors, have limitations including side effects, poor patient adherence, and inadequate addressing of underlying causes, while systemic treatments pose risks and identifying triggers is challenging.
A topical moisturizer composition comprising emollients, occlusives, humectants, emulsifying agents, antioxidants, anti-inflammatory agents, chelating agents, skin barrier protectors, viscosity builders, and other cosmeceutically acceptable excipients, designed to synergistically relieve dry skin symptoms and manage atopic dermatitis symptoms comprehensively.
The composition effectively hydrates the skin, reduces transepidermal water loss, repairs the skin barrier, and minimizes the need for multiple applications, improving patient compliance and overall treatment efficacy by addressing dryness, itching, and inflammation.
Smart Images

Figure IMGF000016_0001_TABLE 
Figure IMGF000016_0002_TABLE 
Figure IMGF000017_0001_TABLE
Abstract
Description
TITLE OF THE INVENTION:TOPICAL COMPOSITION FOR RELIEVING DRY SKIN SYMPTOMS ASSOCIATED WITH ATOPIC DERMATITIS AND ECZEMACROSS-REFERENCE TO RELATED APPLICATIONS AND PRIORITY The present application claims priority from Indian Patent Application number 202521044385 filed on May 7, 2025, incorporated herein by a reference.FIELD OF THE INVENTION
[0001] The topical composition for relieving the dry skin symptoms associated with Atopic Dermatitis / Eczema is disclosed in present invention. These dry skin symptoms include dry and rough skin, redness, itching, inflammatory flares. The composition comprises combination of ingredients that exhibits synergistic effects for the relieving the dry skin symptoms associated with Atopic Dermatitis / Eczema. The process for preparation of topical composition is also provided herein.BACKGROUND OF THE INVENTION
[0002] Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin. It often begins in childhood but can persist into adulthood or develop later in life. The exact cause of atopic dermatitis is not fully understood, but it is believed to result from a combination of genetic, environmental, and immune system factors. Individuals with atopic dermatitis typically have a compromised skin barrier, making their skin more susceptible to irritants, allergens, and infections. Common triggers include soaps, detergents, stress, certain foods, weather changes, and allergens like dust mites or pet dander. The condition often occurs in people with a personal or family history of allergies, asthma, or hay fever. While not contagious, atopic dermatitis can significantly affect a person's quality of life due to intense itching, sleep disturbances, and visible skin changes. Management involves moisturizing the skin regularly, avoiding triggers, and using anti-inflammatory treatments like topical corticosteroids or calcineurin inhibitors during flare-ups.
[0003] The treatment regimen for atopic dermatitis focuses on relieving symptoms, repairing the skin barrier, and preventing flare-ups. A cornerstone of management is regular use of moisturizersor emollients to keep the skin hydrated and reduce dryness and itching. During flare-ups, topical corticosteroids are commonly prescribed to reduce inflammation and itching, while non-steroidal options like calcineurin inhibitors (e.g., tacrolimus or pimecrolimus) are used for sensitive areas or long-term maintenance. In more severe cases, phototherapy or systemic treatments such as oral corticosteroids, cyclosporine, or newer biologic drugs like dupilumab may be considered. Antihistamines can also be used to help control itching, especially at night. Additionally, identifying and avoiding triggers such as allergens, irritants, and stress is vital to managing the condition effectively. A consistent skin care routine and patient education are essential components of a successful long-term treatment plan.
[0004] Topical treatment of atopic dermatitis aims to reduce inflammation, relieve itching, and promote skin healing. The primary treatment includes the application of topical corticosteroids, which are effective in quickly reducing redness, swelling, and discomfort. The potency of the steroid is selected based on the severity of the condition and the location of the affected skin milder steroids for the face and sensitive areas, and stronger ones for thicker skin like the palms or soles. In cases where corticosteroids are not suitable for long-term use, topical calcineurin inhibitors such as tacrolimus or pimecrolimus may be prescribed as steroid-sparing agents. Cool compresses and soothing lotions like calamine may provide additional relief in the early stages. Antiseptic or antibiotic creams might also be used if secondary bacterial infection is suspected. Moisturizers are important to support skin barrier repair and prevent further irritation. Avoiding known triggers and irritants is crucial to prevent worsening or recurrence of acute episodes.
[0005] Numerous topical compositions are disclosed in the state of the art for the treatment of Atopic Dermatitis.
[0006] KR20110116593 discloses a topical skin composition having an atopic dermatitis improving ability, and more particularly, to a topical skin topical composition for preventing and treating atopic dermatitis, including a windproof extract, a golden extract, and a sci extract. The external composition for skin having atopic dermatitis improving ability according to the present invention contains natural herbal extracts, windproof, golden and shiho extracts, which have high antioxidant and free radical scavenging ability while minimizing irritation and toxicity to skin cells. It can antagonize the pathological actions of dermatitis, thereby substantially improving atopic dermatitis.
[0007] KR20230100908 discloses relates to a composition for skin external application for the treatment of atopic dermatitis. More specifically, the composition contains allicin and citron extracts as active components. The external skin composition for the treatment of atopic dermatitis containing allicin of the present invention has the advantage of ultimately alleviating atopic dermatitis by inhibiting the expression of TSLP and sterilizing staphylococci.
[0008] WO2022152893 discloses a dermatological composition comprising at least one extract based on wheat germ polar lipids for the prevention and / or treatment of atopic dermatitis following an allergic reaction to dust mites in an individual.
[0009] WO2024167327 discloses a composition for preventing or treating atopic dermatitis, comprising, as an active ingredient, novel peptidomimetic which effectively controls various types of cytokines that cause atopy.
[0010] W02020091232 discloses a composition for prevention, improvement or treatment of atopic dermatitis, comprising a Lumbricus rubellus extract as an active ingredient, wherein the Lumbricus rubellus extract and a fraction thereof are not cytotoxic, reduce production of NO, as well as reduce production of inflammation-induced chemokine RANTES with increased secretion from human skin keratinocytes (HaCaT cell) by TNF-a and IFN-y, and therefore can be utilized as a composition for preventing or treating various inflammatory diseases.
[0011] Current treatment regimens for atopic dermatitis, while often effective in relieving symptoms, come with several limitations and challenges. Prolonged use of topical corticosteroids, especially high-potency ones, can lead to side effects such as skin thinning (atrophy), stretch marks, and even suppression of the skin’s natural immune response. Patients may also experience rebound flares when corticosteroids are discontinued abruptly. Calcineurin inhibitors, though useful as steroid alternatives, can cause a burning or stinging sensation on application and are often more expensive. Many topical treatments require consistent application, which can be inconvenient and lead to poor patient adherence. Additionally, some regimens do not adequately address the underlying cause of the dermatitis or prevent recurrence, focusing instead on symptom management. Overuse of topical antibiotics can lead to resistance, while systemic treatments for severe cases may carry risks of systemic side effects. Finally, identifying and avoiding individual triggers can be difficult, which makes long-term control challenging for many patients.
[0012] Present invention provides the topical moisturiser composition for treatment of / application in Atopic Dermatitis. Moisturisers are the main stay and co-prescription in all types and stages ofatopic dematitis treatment protocol. A present formulation for the treatment of atopic dermatitis is designed to address various aspects of the condition, including dry and rough skin, skin barrier impairment, inflammation, redness and itching. The composition according to present invention helps to hydrate the skin, reduce TEWL, repair skin barrier, reduce redness, itching and inflammation in Atopic Dermatitis. The combination of these active and supportive ingredients in a single formulation ensures comprehensive management of dry skin condition and associated symptoms of atopic dermatitis while minimizing the need for multiple separate applications, thus improving patient compliance and overall treatment efficacy.SUMMARY OF THE INVENTION
[0013] This summary is provided to introduce a selection of concepts in a simplified form that is further described below in the detailed description section. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
[0014] According to the teachings of the present invention there is provided the composition for topical application for relieving the dry skin symptoms associated with Atopic Dermatitis / Eczema.
[0015] In another aspect the present invention provides topical composition comprising multiple components that works synergistically for providing relief from Atopic Dermatitis and symptoms of dry skin, barrier repair, itching, irriation, inflammation, redness and skin flares.
[0016] In another aspect, the present invention provides the topical composition comprising multiple components selected from various categories comprising but not limiting to Emollient, Emulsifying Agent, Occlusive, Humectant, Antioxidant, Anti-inflammatory, anti-itching agent / anti-histaminic, Chelating Agent, Skin Barrier Improver, Viscosity Builder, moisturizers, skin smoothener, skin protectant, Increases Skin NMF and one or more cosmeceutically acceptable excipients.
[0017] In yet another aspect, the composition is provided in the form of Moisturising Lotion.
[0018] In another aspect, the present invention provides the process for preparation of spreadable composition for topical application to provide relief from dry skin symptoms associated with Atopic Dermatitis / Eczema.
[0019] Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments.DETAILED DESCRIPTION OF THE INVENTION
[0020] The present invention provides the topical composition characterized by high suitability for application for providing relief from dry skin symptoms associated with Atopic Dermatitis / Eczema.
[0021] Aspects of the present invention are best understood by reference to the description set forth herein. All the aspects described herein will be better appreciated and understood when considered in conjunction with the following descriptions. It should be understood, however, that the following descriptions, while indicating preferred aspects and numerous specific details thereof, are given by way of example only and should not be treated as limitations. Changes and modifications may be made within the scope herein without departing from the spirit and scope thereof, and the present invention herein includes all such modifications.
[0022] All publications herein are incorporated by reference to the same extent as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.
[0023] Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0024] In some embodiments, numbers have been used for quantifying weights, percentages, ratios, and so forth, to describe and claim certain embodiments of the invention and are to be understood as being modified in some instances by the term “about.” Accordingly, in some embodiments, the numerical parameters set forth in the written description and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters should be construed inlight of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The numerical values presented in some embodiments of the invention may contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0025] Various terms as used herein are shown below. To the extent a term used in a claim is not defined below, it should be given the broadest definition persons in the pertinent art have given that term as reflected in printed publications and issued patents at the time of filing.
[0026] As used in the description herein and throughout the claims that follow, the meaning of “a,” “an,” and “the” includes plural reference unless the context clearly dictates otherwise. Also, as used in the description herein, the meaning of “in” includes “in” and “on” unless the context clearly dictates otherwise.
[0027] Unless the context requires otherwise, throughout the specification which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense that is as “including, but not limited to.”
[0028] The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein.
[0029] The headings and abstract of the invention provided herein are for convenience only and do not interpret the scope or meaning of the embodiments.
[0030] The term, "therapeutically effective amount" as used herein refers to an amount of a formulation or component, effective in producing the desired therapeutic response in a particular patient (subject) suffering from a disease or disorder.
[0031] As used herein the term "topical application" describes application onto a biological surface, e.g., an affected skin or membrane. Hence, the phrase "a composition for topical application" describes a composition that is applied, preferably by spreading, on, for example, skin, eye, ear, scalp, hair or membrane of a subject.
[0032] As used herein, the term "process" and the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, thosemanners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
[0033] In one embodiment, the present invention provides the topical composition for relieving the dry skin symptoms associated with Atopic Dermatitis / Eczema.
[0034] In another embodiment, the present invention provides the topical composition for the relief from dry skin symptoms associated with Atopic Dermatitis / Eczema, wherein the said composition comprises multiple ingredients that synergistically provides effectiveness for management of dry skin symptoms associated with Atopic Dermatitis.
[0035] In yet another embodiment, the present invention provides the topical composition for treatment of atopic dermatitis comprising Emollient, Occlusive, Humectant Emulsifying Agent, Antioxidant, Anti-inflammatory, Anti-itch / Anti-histaminic Chelating Agent, Skin Barrier Protector, Viscosity Builder, moisturizers, skin smoothener, Increases Skin NMF, skin protectant, a humectant (Oatmeal) and one or more cosmeceutically acceptable excipients, and one or more cosmeceutically acceptable excipients.
[0036] Emollients such as ceramides restores and maintains the skin’s natural barrier. These moisturizing agents work by filling in the gaps between skin cells with lipids, thereby reducing transepidermal water loss and protecting the skin from environmental irritants and allergens. Regular use of emollients helps to soothe dryness, reduce itching, and prevent flare-ups by keeping the skin hydrated and supple. They are especially important in both acute and maintenance phases of atopic dermatitis and can enhance the effectiveness of other topical treatments like corticosteroids or calcineurin inhibitors. Emollients should be applied generously and frequently, particularly after bathing, to lock in moisture. Products containing ceramides, glycerin, or natural oils are often preferred for their skin-repairing and soothing properties. Since they are generally safe, free from major side effects, and suitable for all age groups, emollients are considered a cornerstone of long-term atopic dermatitis care.
[0037] Emulsifying agents helps to create stable emulsions that blend oil and water phases, resulting in smooth, easily spreadable creams or lotions. These agents ensure consistent distribution of active ingredients, such as corticosteroids, moisturizers, or anti-inflammatory compounds, across the skin surface. In the context of atopic dermatitis, emulsifying agents enhance the effectiveness of topical formulations by improving their texture, absorption, and patientacceptability. Common emulsifiers used include cetostearyl alcohol, polysorbates, and glyceryl stearate, which also contribute to skin hydration by forming a protective film that reduces transepidermal water loss. By supporting the integrity and usability of therapeutic creams and ointments, emulsifying agents indirectly aid in restoring the skin barrier, relieving dryness, and enhancing the overall treatment outcome for individuals with atopic dermatitis.
[0038] Occlusives forms a physical barrier on the skin surface to prevent transepidermal water loss and protect against external irritants. Occlusive agents are frequently used in emollient formulations to help retain moisture, soothe dry and cracked skin, and support the repair of the compromised skin barrier. By sealing in hydration and enhancing the effectiveness of other active ingredients, occlusives contribute significantly to symptom relief, especially during flare-ups. Their use is particularly beneficial when applied immediately after bathing, as this helps to lock in moisture and maintain skin hydration for longer periods. While generally safe and well-tolerated, some occlusives may feel greasy or heavy on the skin, which can affect patient adherence. Nevertheless, incorporating occlusives into a daily skincare routine is an essential component of managing atopic dermatitis and preventing future flare-ups.
[0039] Antioxidants neutralizes oxidative stress, which plays a significant role in the inflammation and skin barrier dysfunction associated with the condition. In atopic dermatitis, elevated levels of reactive oxygen species (ROS) can damage skin cells and exacerbate inflammation. Antioxidants such as vitamin E, vitamin C, coenzyme Q10, and plant-derived polyphenols (like green tea extract or resveratrol) help to scavenge these harmful free radicals, thereby reducing oxidative damage and supporting skin healing. Topical formulations containing antioxidants not only help in calming inflamed skin but also aid in restoring the skin’s natural protective barrier. Some antioxidants also possess anti-inflammatory and moisturizing properties, making them beneficial as adjuncts to standard therapies. Incorporating antioxidants into the treatment regimen may improve outcomes, reduce reliance on corticosteroids, and support long-term skin health in patients with atopic dermatitis.
[0040] Anti-inflammatory agents helps to reduce the underlying skin inflammation responsible for redness, swelling, and itching. Topical corticosteroids are the most commonly used antiinflammatory medications and are effective in managing acute flare-ups by suppressing the overactive immune response. Their potency is chosen based on the severity of the condition and the area of application, with milder formulations used for the face and stronger ones for thickerskin. In addition to corticosteroids, non-steroidal anti-inflammatory agents like topical calcineurin inhibitors (e.g., tacrolimus and pimecrolimus) are used, particularly for sensitive skin areas or long-term maintenance, as they carry a lower risk of skin thinning. Newer treatments such as phosphodiesterase-4 (PDE4) inhibitors, like crisaborole, offer additional non-steroidal options with anti-inflammatory effects. These medications help control inflammation, reduce flare frequency, and improve skin appearance and comfort, making them essential in the long-term management of atopic dermatitis.
[0041] Chelating agents improves the effectiveness of topical formulations and address the imbalance of metals or minerals in the skin. These agents, such as disodium EDTA or citric acid, work by binding to and removing metal ions like calcium, magnesium, or iron, which may contribute to inflammation and skin irritation in individuals with atopic dermatitis. By reducing the presence of these metals, chelating agents can help prevent oxidative stress and further irritation that may exacerbate the condition. Additionally, chelating agents may enhance the absorption of other active ingredients, allowing for better penetration and efficacy of antiinflammatory agents or moisturizers. While not always the primary treatment, incorporating chelating agents into topical creams or ointments can offer an added benefit, particularly for individuals with sensitive or compromised skin barriers.
[0042] Skin barrier protectors repairs and strengthens the skin's natural protective barrier, which is often compromised in individuals with the condition. These products typically contain ingredients like ceramides, fatty acids, and cholesterol, which are essential components of the skin’s lipid barrier. By replenishing these lipids, skin barrier protectors help prevent excessive moisture loss and shield the skin from irritants, allergens, and harmful microorganisms that can exacerbate dermatitis. Regular use of these protectors can significantly reduce the frequency and severity of flare-ups, improve skin hydration, and enhance overall skin health. Unlike topical corticosteroids or other anti-inflammatory treatments, skin barrier protectors are often well-tolerated for long-term use and can be safely applied to sensitive areas like the face and around the eyes, making them an essential part of a comprehensive treatment regimen for atopic dermatitis.
[0043] Viscosity builders enhances the texture and consistency of topical treatments, making them easier to apply and ensuring better adherence to the skin. These agents, such as xanthan gum, hydroxyethylcellulose, and carbomers, help increase the viscosity of creams, lotions, or gels, allowing for smoother application and more controlled delivery of active ingredients. Byimproving the spreadability of the formulation, viscosity builders ensure that the treatment stays in place on the skin, providing a longer-lasting effect. This is especially important in treating atopic dermatitis, as it can help prevent the product from rubbing off or evaporating quickly, enhancing the efficacy of other active ingredients like corticosteroids, moisturizers, and anti-inflammatory agents. Additionally, the thicker consistency may help seal moisture into the skin, reducing dryness and irritation, and improving overall skin hydration, which is crucial for managing the symptoms of atopic dermatitis.
[0044] Moisturizers restores and maintains the skin’s natural barrier function, which is often compromised in individuals with the condition. Regular use of emollients helps to lock in moisture, prevent skin dryness, and reduce irritation and itching, which are hallmark symptoms of atopic dermatitis. Moisturizers containing ingredients such as ceramides, hyaluronic acid, glycerin, and fatty acids are particularly beneficial, as they mimic the skin's natural lipids and help to repair the skin barrier. Applying moisturizers immediately after bathing or washing can significantly improve skin hydration and reduce the frequency and severity of flare-ups. Some moisturizers are formulated with added anti-inflammatory or soothing agents like colloidal oatmeal or aloe vera to further calm irritated skin. Consistent use of moisturizers not only alleviates discomfort but also enhances the overall effectiveness of other treatments, making it a cornerstone of managing atopic dermatitis.
[0045] Skin smootheners improves skin texture, reduce roughness, and restore the skin barrier. These ingredients, such as ceramides, fatty acids, and alpha-hydroxy acids (AHAs), work by replenishing the skin’s natural lipids and promoting the shedding of dead skin cells, which can accumulate in dry, inflamed patches. Ceramides, in particular, help to repair the skin barrier, preventing moisture loss and reducing the risk of further irritation. Fatty acids like linoleic acid, often found in plant-based oils, help to hydrate and smooth the skin, while AHAs provide gentle exfoliation to improve skin tone and texture. When incorporated into moisturizers or ointments, skin smootheners can enhance the overall effectiveness of atopic dermatitis treatments by softening rough, scaly skin and reducing the appearance of plaques. These ingredients are especially helpful during flare-ups, as they support skin healing and promote a smoother, more resilient skin surface.
[0046] Increasing skin Natural Moisturizing Factor (NMF) plays a key role in maintaining the skin's hydration, elasticity, and overall barrier function. NMF is a group of water-solublecompounds, primarily amino acids, lactic acid, and urea, that help the skin retain moisture and prevent dryness. In atopic dermatitis, the skin barrier is compromised, leading to excessive water loss and dryness, which exacerbates inflammation and itching. By increasing NMF levels, either through topical treatments or formulations that contain humectants like glycerin or urea, the skin's ability to attract and retain moisture is enhanced, which helps to restore the barrier function and reduce irritation. This also leads to reduced sensitivity to environmental triggers and irritants. Topical treatments designed to boost NMF can provide long-term benefits, improving the skin's resilience and reducing the frequency and severity of flare-ups, making it an essential part of the overall management of atopic dermatitis.
[0047] In yet another embodiment, the present invention provides the topical composition as an atleast one dosage form selected from but not limiting to cream, ointment, gel, lotion, foam, powder, paste, aerosol, patch, balm, spray, mousse, emollient, emulsion, serum, wipe and the like.
[0048] In a preferred embodiment, the present invention provides the topical composition for treatment of atopic dermatitis, comprising:one or more Emollient,one or more occlusive agent,one or more humectant,one or more emulsifying agent,atleast one moisturising agent,atleast one skin protectant,atleast one antioxidant,one or more skin barrier restoring agent,atleast one chelating agent,one or more skin smoothener,atleast one Skin NMF improver,one or more anti-inflammatory,One or more anti-itching / Anti-histamininc agentOne or more nourishing aminoacidsviscosity builder / s,and one or more cosmeceutically acceptable excipients,wherein any ingredient of the said composition can perform one or more functionalities.
[0049] In a preferred embodiment, the present invention provides the topical composition for treatment of atopic dermatitis, comprising:1-10% of one or more emollients,0.5% to 10% of one or more occlusive agent2% to 20% of one or more humectant,1% to 10% of one or more emulsifying agent,2% to 25% of atleast one moisturising agent,0.1 % to 1.0% of atleast one antioxidant,1% to 5% of one or more skin barrier restoring agent,0.01% to 0.2% of atleast one chelating agent,0.01% to 5% of one or more skin smoothener,1% to 10% of atleast one Skin NMF improver,1% to 10% of one or more anti-inflammatory,1% to 5% of viscosity builder / s,0.1 % to 2% of ceramide based ingredients,0.1 % to 1 % of Allantoin,0.5% to 5% of Oat Meal Extract skin protectant,0.1 % to 3% of Tetra Hydrocurcumin - anti-inflammatory, anti-oxidant0.01% to 0.2% of combination of Glycyrrhiza Inflate Ext.,0.001% to 0.1% of 99.99 % Resveratrol,0.5% to 5% of Dimethicone,0.2% to 2% of combination of Xylitylglucoside, Anhydroxylitol and Xylitol,0.5% to 5% of Hydroxyphenyl Propamidobenzoic Acid,0.3% to 3% of Amino Acid Complex 17and one or more cosmeceutically acceptable excipients,wherein any ingredient of the said composition can perform one or more functionalities.
[0050] In yet another embodiment, the present invention provides good to excellent spreadability of the topical formulation according to present invention.
[0051] In yet another embodiment, the present invention provide the topical formulation having pH levels of between 5.0 and 6.0 which is suitable for natural skin pH.
[0052] In yet another embodiment, the present invention provides the topical formulation providing fast to moderate absorption of the ingredients through skin within 1-15 minutes.
[0053] In yet another embodiment, the Viscosity levels of topical formulation typically range from 5,000 to 50,000 centipoise (cP).
[0054] In yet another embodiment, the present invention provides the topical formulation with adequate emolliency, occlusivity, greasiness, stickiness, and smoothness.
[0055] In yet another embodiment, the present invention provides the process for preparation of composition for topical application to provide relief from dry skin symptoms associated with atopic Dermatitis / Eczema.Clinical Trial evaluation of topical composition;
[0056] In yet another embodiment, the topical composition is subjected to study of safety and efficacy of formulation through subject self evaluation, dermatological evaluation for cosmetic acceptability, dermatological evaluation for efficacy, mexametry, and chromametry and the like.
[0057] The present invention is subjected to in-vivo efficacy and safety in terms of reduction of dry skin symptoms associated with atopic Dermatitis / Eczema.
[0058] In yet another embodiment, The present invention was subjected for evaluation of efficacy and in use tolerance of the Test Product in participants with eczema. Skin hydration and skin barrier properties was recorded using instrumentation and clinical grading using EASI score.
[0059] The endpoints were as follows:Primary Endpoints• EASI score (Baseline, 1 week, Day 28).• Skin Hydration Measurement of Stratum corneum using MoistureMeter SC (Baseline, 5 mins, 1 hour, 1 week, Day 28)• Trans epidermal water loss by VapoMeter (Baseline, 5 mins, 1 hour, 1 week, Day 28) • Self-assessment questionnaire for efficacy (1 week, Day 28).• Self-assessment of reduction in itching (Baseline, 1 hour, 1 week, Day 28)• Self-assessment in overall improvement in the quality of life (Baseline, 1 week, Day 28)Secondary Endpoints• Clinical evaluation for tolerance (1 hour, 1 week, Day 28).• Self-assessment questionnaire for skin tolerance (1 hour 1 week, Day 28).
[0060] In yet another embodiment, the Primary Evaluation criteria for clinical study were Clinical evaluation using EASI scores, Skin Hydration Measurement of Stratum corneum using MoistureMeter SC, Trans epidermal water loss by VapoMeter, Self-assessment questionnaire for efficacy, Self-assessment of reduction in itching, Self-assessment in overall improvement in the quality of life.
[0061] In yet another embodiment, Clinical evaluation was done using EASI (Eczema Area and Severity Index) scores. An EASI score is a tool used to measure the extent (area) and severity of atopic eczema (Eczema Area and Severity Index). Firstly, the area of involvement must be visually estimated in each of the 4 body regions separately (head and neck, upper extremities, trunk, and lower extremities) and assigned an area score: 1 (1%–9%), 2 (10%-29%), 3 (30%-49%), 4 (50%-69%), 5 (70%-89%), and 6 (90%-100%). The severity score is the sum of the intensity scores for four signs. The four signs are:1. Redness (erythema, inflammation)2. Thickness (induration, papulation, swelling — acute eczema)3. Scratching (excoriation)4. Lichenification (lined skin, furrowing, prurigo nodules — chronic eczema).
[0062] The average intensity of each sign in each body region is assessed as: none (0), mild (1), moderate (2) and severe (3).
[0063] Calculation: Severity score = redness intensity + thickness intensity + scratching intensity + lichenification intensity.
[0064] For each region, the severity score will be multiplied by the area score and by a multiplier. The multiplier will be for each body site:Head and neck: severity score x area score x 0.1Trunk: severity score x area score x 0.3Upper limbs: severity score x area score x 0.2Lower limbs: severity score x area score x 0.4The minimum EASI score is 0 and maximum EASI score is 72
[0065] In yet another embodiment, the Skin Hydration Measurement of Stratum corneum was conducted using MoistureMeter SC. The MoistureMeter SC measures the hydration of the skinsurface, stratum corneum. The skin is electrically layered structure. The electrical properties of these layers are related to their water content.
[0066] The probe, the skin surface and the deeper skin layers form a structure similar to an electrical capacitor. The measured capacitance is proportional to the water content of the surface layer of the skin. The higher the reading, the higher the moisture content.
[0067] In yet another embodiment, Transepidermal water loss was conducted using VapoMeter. The VapoMeter is equipped with a closed cylindrical chamber that contains sensors for relative humidity and temperature. There is a linear increase of relative humidity (RH%) in the chamber shortly after placing the device in contact with the skin. The TEWL (Trans Epidermal Water Loss) is calculated from the increase in RH%. Values of ambient RH (%) and temperature (0C) are recorded before skin contact. The chamber is passively ventilated between measurements. Reduction in the VapoMeter readings indicates prevention of water loss from skin.
[0068] In yet another embodiment, Self-assessment questionnaire was recorded for efficacy. A self-assessment questionnaire was administered to participants to understand their perception of efficacy of product.
[0069] In yet another embodiment, Self-assessment was recorded for reduction in itching. A selfassessment questionnaire was administered to capture reduction in itching on a scale as follows (0=None, l=Mild, 2=Moderate, 3=severe).
[0070] In yet another embodiment, Self-assessment was recorded for overall improvement in the quality of life. A self-assessment questionnaire was administered to participants to understand their perception of overall improvement in the quality of life.
[0071] In yet another embodiment, Safety Variable(s) were recorded by Clinical evaluation for skin tolerance (1 hour, 1 week, Day 28) and Self-assessment questionnaire for skin tolerance 1 hour 1 week, Day 28). A self-assessment questionnaire was administered to participants to capture skin tolerance.
[0072] In yet another embodiment, the Data Quality Assurance was conducted using Case Report forms by checking for recruitment, exactitude of data and inclusion and exclusion criteria, compliance of given information during the length of study by a Researcher and / or QA Department. In house checks and audits regarding trial and Quality Management system were carried out by Quality Department.
[0073] The present disclosure is further described in light of the following experiments which are set forth for illustration purpose only and not to be construed for limiting the scope of the disclosure. The following experiments can be scaled up to industrial / commercial scale and the results obtained can be extrapolated to industrial scale.Example No. 01: Formulation of Topical Moisturising composition;Example No. 02: Formulation of Topical Moisturising composition:Example No.03: Formulation of Topical Moisturising composition;Manufacturing Procedure:Step I: In main vessel take DM water and add oat meal, stir for 30 min to obtained lumps free mixture, then heat upto 70°C, then add Di Sodium EDTA and Allantoin and stir for 15 min. Step-II: Add Cetostearyl Alcohol, Emulsifying Wax, Capryl ic / Capric Triglyceride, Glyceryl Stearate (and) PEG-100 Stearate, Shea Butter, Ceramide EOP, Ceramide NS, Ceramide NP, Ceramide AS, Ceramide AP, Hydrogenated Lecithin, Cholesterol, Vitamin E and Butylated Hydroxytoluenein oil vessel and heat upto 70°C with stirring.Step III: Add step I to step II at 70°C and homogenize for 20 min with 2000 rpm.Step IV: Take tetra hydrocurcumin in active vessel and heat to upto 65°C, mix well and add into main vessel.Step V: Take Glycyrrhiza Inflate Ext. and Propylene Glycolin active vessel and heat to upto 65°C, mix well and add into main vessel.Step VI: Take Resveratrol 99.99 %in active vessel and heat to upto 65°C, mix well and add into main vessel.Step VII: Then add material of Polyacrylate- 13 (and) Polyisobutene (and) Polysorbate Triethanolamine, Dimethicone one by one and homogenize for 20 min.Step VIII: Take Sodium Hyaluronate in active vessel and mix well in water at room temp, and add into main vessel and homogenized for 10 min with stirring.Step IX: Then add material of Xylitylglucoside, Anhydroxylitol and Xylitol, Butylene Glycol (and) Pentylene Glycol (and) Hydroxyphenyl Propamidobenzoic Acid, Hydroxyethyl Urea, Amino Acid Complex 17, Phenoxyethanol and Ethylhexylglycerin one by one and stir for 10 min at the time of every addition.• Evaluation of finished composition based on clinical study results:1) EASI scores:
[0074] The change in mean EASI score over study duration was recorded using by Wilcoxon Sign Rank Test as shown in Table 1 and Figure no. 01Table 1: Changes in mean EASI score over study durationSignificantResult:
[0075] Decrease in values indicates improvement in eczema lesions was observed.At baseline, mean EASI score was 4.21.After 1 week of application, mean EASI score showed a significant decrease of 4.5% from baseline.After 28 Days of application, mean EASI score showed a significant decrease of 15.4% from baseline.2) Changes in mean skin hydration (MMSC readings) over study duration:
[0076] Changes in mean skin hydration (MMSC readings) over study duration was recorded by Student ‘t’ Test as shown in Table no. 2 and Figure no. 02Table 2: Changes in mean skin hydration (MMSC readings) over study duration* SignificantResult:
[0077] Increase in values indicates increase in skin hydration.At baseline, mean MMSC was 4.78.After 5 mins of application, mean MMSC showed a significant increase of 70.7% from baseline.After 1 hour of application, mean MMSC showed a significant increase of 1.05 times from baseline.After 1 week of application, mean MMSC showed a significant increase of 65.3% from baseline.After 28 Days of application, mean MMSC showed a significant increase of 95.8% from the baseline.3) Trans epidermal water loss by VapoMeter;
[0078] Changes in mean TEWL (VapoMeter readings) over study duration was recorded by Student ‘t’ Test as shown in Table no. 3 and Figure no. 3:Table 3: Changes in mean TEWL (VapoMeter readings) over study duration* SignificantResult:
[0079] Decrease in values indicates decrease in TEWLAt baseline, mean Vapometer was 11.38.After 5 mins of application, mean Vapometer showed a significant decrease of 7.7% from baseline.After 1 hour of application, mean Vapometer showed a significant decrease of 17.0% from baseline.After 1 week of application, mean Vapometer showed a significant decrease of 12.0% from baseline.After 28 Days of application, mean Vapometer showed a significant decrease of 19.0% from baseline.4) Self-assessment questionnaire for efficacy:
[0080] The self-assessment questionnaire for efficacy was recorded and the percentage of participants reporting top 2 scores for various parameters are shown in Table no: 4Table 4: % of participants reporting top 2 scores (agree+ Strongly agree) for various parameters:5) Self-assessment of reduction in itching:
[0081] The self-assessment questionnaire for itching was recorded by WILCOXON SIGNED-RANK TEST and Changes in mean score of itching based on participant feedback are shown in table no: 05 and figure no. 04.Table 5: Changes in mean score of itching based on participant feedbackResults: Decrease in values indicates decrease in itchingAt baseline, mean score of itching was 2.03.After 1 hour of application, mean score of itching showed a significant decrease of 12.8% from baseline.After 1 week of application, mean score of itching showed a significant decrease of 47.8% from baseline.After 28 Days of application, mean score of itching showed a significant decrease of 71.4% from baseline.6) Self-assessment in overall improvement in the quality of life:
[0082] The self-assessment in overall improvement in the quality of life was recorded and the percentage of participants reporting by Chi Square Test itchy, sore, painful or stinging skin are shown in Table no: 6Table 6: % of participants reporting Itchy, sore, painful or stinging skin* SignificantResult:
[0083] % of participants experiencing lot of itchy, sore, painful or stinging skin was tracked over study duration. Decrease in % of participants indicates improvement.At baseline, 67.8% of the participants reported experiencing a lot of itchy, sore, painful or stinging skin.After 1 week of application, 19.4% of the participants reported experiencing a lot of itchy, sore, painful or stinging skin which showed significant decrease from baseline.After 28 days of application, 6.5 % of the participants reported experiencing a lot of itchy, sore, painful or stinging skin which showed significant decrease from baseline.
[0084] Self-assessment in overall improvement in the quality of life (Baseline, 1 week, Day 28) is provided as follows:i) % of participants reporting Itchy, sore, painful or stinging skin;At baseline, 67.8% of the participants reported experiencing a lot of itchy, sore, painful or stinging skin.After 1 week of application, 19.4% of the participants reported experiencing a lot of itchy, sore, painful or stinging skin which showed significant decrease from baseline, i.e.71.38% of the baseline participants did not experience itchy, sore, painful or stinging skin. After 28 days of application, 6.5 % of the participants reported experiencing a lot of itchy, sore, painful or stinging skin which showed significant decrease from baseline.i.e. 95.87 % of the baseline participants did not experience itchy, sore, painful or stinging skin.ii) % of participants reporting they were embarrassed or self-conscious because of their skin;At baseline, 77.4% of the participants reported that they had been a lot embarrassed or self-conscious because of their skin.After 1 week of application, 32.3% of the participants reported that they had been a lot embarrassed or self-conscious because of their skin which showed significant decrease from baseline, i.e. 58.27 % of the baseline participants were not embarrassed or self- conscious because of their skin.After 28 days of application, 6.4 % of the participants reported that they had been a lot embarrassed or self-conscious because of their skin which showed significant decrease from baseline, i.e. 91.73 % of the baseline participants were not embarrassed or self- conscious because of their skin,iii) % of the participants reporting that skin interfered with going shopping or looking after home or garden:At baseline, 87.0% of the participants reported that skin interfered with going shopping or looking after home or garden a lot.After 1 week of application, 32.3% of the participants reported that skin interfered with going shopping or looking after home or garden, a lot which showed a significant decrease from baseline, i.e. 62.87 % of the baseline participants skin did not interfere with going shopping or looking after home or garden.After 28 days of application, 12.9% of the participants reported that skin interfered with going shopping or looking after home or garden, a lot which showed a significant decrease from baseline, i.e. 85.17 % of the baseline participants skin did not interfere with going shopping or looking after home or garden.iv) % of participants reporting that their skin affected any social or leisure activities:At baseline, 87.1% of participants reported that their skin affected any social or leisure activities a lot.After 1 week of application, 22.6% of the participants reported that their skin affected any social or leisure activities a lot which showed a significant decrease from baseline, i.e.74.05% of the baseline participants skin did not affecte any social or leisure activities. After 28 days of application, 9.7% of the participants reported that their skin affected any social or leisure activities a lot, which showed a significant decrease from baseline, i.e.88.85% of the baseline participants skin did not affect any social or leisure activities. v) % of participants reporting that their skin been a problem at work or studying:At baseline, 83.9% of participants reported that their skin had been a problem at work or studying a lot.After 1 week of application, 22.6% of the participants reported that their skin had been a problem at work or studying a lot which showed a significant decrease from baseline i.e.73.06% of the baseline participants skin had not been a problem at work or studying: After 28 days of application, 12.9% of the participants reported that their skin had been a problem at work or studying a lot which showed a significant decrease from baseline, i.e.84.62% of the baseline participants skin had not been a problem at work or studying,CONCLUSION:
[0085] At the end of study, after application of present composition, for 28 days, it can be concluded that test product was efficacious in:Significantly reducing EASI score,Significantly increasing skin hydration,Significantly reducing Trans epidermal water loss.Significantly reducing itching.More than 80% participants agreed that skin had become hydrated, and soft and smooth.More than 90% participants agreed itching had reduced and that they liked the product.More than 87% participants agreed significant improvement in Quality of Life. The Product was well tolerated.
[0086] The embodiments of the invention shown and discussed herein are merely illustrative of modes of application of the present invention. Reference to details in this discussion is not intended to limit the scope of the claims to these details, or to the figures used to illustrate the invention.
Claims
CLAIMS:
1. A topical composition for alleviating dry skin and itching associated with atopic dermatitis or eczema, comprising:1-10 wt.% of one or more emollients;0.5-10 wt.% of one or more occlusive agents;2-20 wt.% of one or more humectants;1-10 wt.% of one or more emulsifying agents;2-25 wt.% of one or more moisturizing agents;0.5-5 wt.% of one or more skin protectants;0.1-1 wt.% of one or more antioxidants;1-5 wt.% of one or more skin barrier restoring agents;0.01-0.2 wt.% of one or more chelating agents;0.01-5 wt.% of one or more skin smoothening agents;1-10 wt.% of one or more skin natural moisturizing factor (NMF) improvers;1-10 wt.% of one or more anti-inflammatory agents;one or more anti-itching or antihistaminic agents;0.3-3 wt.% of one or more nourishing amino acids;1-5 wt.% of one or more viscosity builders;0.1-2 wt.% of ceramide-based ingredients;0.1-1 wt.% of allantoin;0.001-0.1 wt.% of resveratrol having a purity of about 99.99%;0.5-5 wt.% of dimethicone;0.2-2 wt.% of a combination of xylitylglucoside, anhydroxylitol, and xylitol;0.5-5 wt.% of hydroxyphenyl propamidobenzoic acid; andone or more cosmeceutically acceptable excipients,wherein one or more ingredients perform multiple functional roles, and wherein the composition is configured to reduce itching, reduce transepidermal water loss, repair a damaged skin barrier, increase skin hydration, and improve quality of life.
2. The topical composition according to claim 1, wherein the composition is formulated as a cream, ointment, gel, lotion, foam, powder, paste, aerosol, patch, balm, spray, mousse, emollient, emulsion, serum, or wipe.
3. The topical composition according to claim 1, wherein the composition exhibits good to excellent spreadability and has a viscosity in the range of 5,000 to 50,000 centipoise (cP).
4. The topical composition according to claim 1, wherein the composition has a pH in the range of 5.0 to 6.0, corresponding to the natural pH of human skin.
5. The topical composition according to claim 1, wherein the composition is absorbed into the skin within 1 to 15 minutes following topical application.
6. The topical composition according to claim 1, wherein the emollients are selected from ceramides, glycerin, natural oils, and combinations thereof.
7. The topical composition according to claim 1, wherein the occlusive agents are selected from petrolatum, dimethicone, mineral oil, waxes, and combinations thereof.
8. The topical composition according to claim 1, wherein the antioxidants are selected from vitamin E, vitamin C, resveratrol, coenzyme Q10, green tea extract, polyphenols, and combinations thereof.
